Abstract
Novel drug delivery systems are one of the widely used delivery systems. In the present scenario, amongst them, “Drug Loaded Erythrocytes” is one of the growing and potential systems for delivery of drugs and enzymes. Erythrocytes are biocompatible, biodegradable, posses long circulation half-life and can be loaded with variety of biologically active substances. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various physical and chemical methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called “resealed erythrocytes”. Surface modification with glutaraldehyde, antibodies, carbohydrates like sialic acid and biotinylation of loaded erythrocytes (biotinylated erythrocytes) is possible to improve their target specificity and to increase their circulation half-life. Upon reinjection the drug loaded erythrocytes serve as slow circulation depots, targets the drug to the reticuloendothelial system (RES), prevents degradation of loaded drug from inactivation by endogenous chemicals, attain steady state concentration of drug and decrease the side-effects of loaded drug. Nowadays, Nanoerythrosomes based drug delivery systems have excellent potential for clinical application.
Keywords: Novel drug delivery system, resealed erythrocytes, drug targeting, nanoerythrosomes
Current Pharmaceutical Design
Title: Drug Loaded Erythrocytes: As Novel Drug Delivery System
Volume: 14 Issue: 1
Author(s): R. S. Hirlekar, P. D. Patel, N. Dand and V. J. Kadam
Affiliation:
Keywords: Novel drug delivery system, resealed erythrocytes, drug targeting, nanoerythrosomes
Abstract: Novel drug delivery systems are one of the widely used delivery systems. In the present scenario, amongst them, “Drug Loaded Erythrocytes” is one of the growing and potential systems for delivery of drugs and enzymes. Erythrocytes are biocompatible, biodegradable, posses long circulation half-life and can be loaded with variety of biologically active substances. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various physical and chemical methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called “resealed erythrocytes”. Surface modification with glutaraldehyde, antibodies, carbohydrates like sialic acid and biotinylation of loaded erythrocytes (biotinylated erythrocytes) is possible to improve their target specificity and to increase their circulation half-life. Upon reinjection the drug loaded erythrocytes serve as slow circulation depots, targets the drug to the reticuloendothelial system (RES), prevents degradation of loaded drug from inactivation by endogenous chemicals, attain steady state concentration of drug and decrease the side-effects of loaded drug. Nowadays, Nanoerythrosomes based drug delivery systems have excellent potential for clinical application.
Export Options
About this article
Cite this article as:
Hirlekar S. R., Patel D. P., Dand N. and Kadam J. V., Drug Loaded Erythrocytes: As Novel Drug Delivery System, Current Pharmaceutical Design 2008; 14 (1) . https://dx.doi.org/10.2174/138161208783330772
DOI https://dx.doi.org/10.2174/138161208783330772 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Gold Coordination Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Antivirals at the Mirror: The Lack of Stereospecificity of Some Viral and Human Enzymes Offers Novel Opportunities in Antiviral Drug Development
Current Drug Targets - Infectious Disorders Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?
Current Women`s Health Reviews Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets